Stereotactic body radiation therapy for prostate cancer

Hiromichi Ishiyama, Bin S. Teh, Simon S. Lo, Thomas Mathews, Angel Blanco, Robert Amato, Rodney J. Ellis, Nina A. Mayr, Arnold C. Paulino, Bo Xu, Brian E. Butler

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Stereotactic body radiation therapy (SBRT) is a promising treatment option for prostate cancer. Hypofractionation regimens, such as SBRT, may be more advantageous compared with conventional regimens because low α:β ratio of prostate cancer has high sensitivity to dose per fraction. In addition, a smaller and tighter margin with SBRT is expected to provide a low toxicity rate without reducing tumor control. The purpose of this article is to examine radiobiological, technical and clinical aspects of SBRT for prostate cancer.

Original languageEnglish (US)
Pages (from-to)1077-1086
Number of pages10
JournalFuture Oncology
Issue number9
StatePublished - Sep 2011


  • outcome
  • prostate cancer
  • stereotactic body radiation therapy
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Stereotactic body radiation therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this